Lung Cancer

Antonio Passaro, MD, PhD, discusses findings from a phase IIIb trial for patients with EGFR mutation-positive non–small cell lung cancer and discussed results from other studies investigating ALK and KRAS mutations in patients with NSCLC.

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the impact of immunotherapy in squamous non–small cell lung cancer.

Although study findings have identified tumor mutational burden as an important factor in responses to cancer therapy, establishing a definition for expression of this biomarker and harmonizing assays to measure it have proved challenging.

Viola W. Zhu, MD, PhD, explains how the use of immunotherapy has improved survival for patients with advanced squamous cell non–small cell lung cancer.

Giuseppe L. Banna, MD, consultant, Medical Oncology, Cannizzaro Hospital, discusses the potential for CAR T-cell therapy in the treatment of patients with lung cancer.

Lyudmila A. Bazhenova, MD, sheds light on initial treatment approaches for patients with EGFR-mutant NSCLC and adapted therapeutic strategies at the time of progression.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of targeted therapy in non–small cell lung cancer.

A 2018 Giants of Cancer Care award winner for Lung Cancer, Bruce E. Johnson, MD, has helped define the genomic era in lung cancer care. His notable contributions include characterizing the role that EGFR mutations play in non–small cell lung cancer.

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Health, chief of lung transplantation, head of the Department of Thoracic Surgery, Baylor University Medical Center, discusses the progress that has been made in resectable stage III lung cancer.

Toll-like receptors, a group of proteins that are components of innate immunity, are emerging as promising targets in a new wave of immunotherapies under development.

Ronan J. Kelly, MD, MBA, chief of oncology for the 10 Baylor Scott & White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the outlook of patients with ALK-positive non–small cell lung cancer (NSCLC).

Massimo Di Maio, PhD, medical oncologist, Mauriziano Hospital, professor of medical oncology, University of Turin, discusses the importance of quality of life (QoL) endpoints in clinical trials.

You-cai Zhu, MD, PhD, Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, discusses primary resistance to osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the use of locally ablative therapy in patients with oligometastatic non–small cell lung cancer.

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses the potential of pembrolizumab in the treatment of patients with small cell lung cancer.

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott and White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the treatment of patients with ALK-positive non–small cell lung cancer.

Rolf A. Stahel, MD, professor in the oncology clinic, University Hospital, Zurich, discusses treatment sequencing in stage IV non–small cell lung cancer.

Alfredo Addeo, MD, consultant medical oncologist, University Hospital of Geneva, discusses the need for effective biomarkers in non–small cell lung cancer.

Umberto Malapelle, PhD, assistant professor, University of Naples Federico II, discusses unanswered questions regarding the role of tumor mutational burden in non–small cell lung cancer.

Alfredo Addeo, MD, discusses the uniqueness of the 1-day Lung Cancer Summit and recent therapeutic advancements that have occurred in the lung cancer space.

The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer, now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the IMpower131 study in squamous metastatic non–small cell lung cancer.